<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>BioWorld</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Regulatory actions for May 27, 2026</title>
      <description>
        <![CDATA[Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Autobahn, Cornerstone, Dyne, Gilead, H. Lundbeck, Microbot, Outlook, Pfizer, Pharming, Spectral, Toby.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731430</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731430-regulatory-actions-for-may-27-2026</link>
    </item>
    <item>
      <title>Other news to note for May 27, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: 28bio, Adcedno, Aim Medical, Biocytogen, Biomunex, Bioprotect, Cgbio, Co-Diagnostics, Cosara, Depuy, Dexcom, Gordion, Human Life Foundation Models, Human Longevity, Insilico, Jiangxi Kvvit, Merck, Merz, Minmaxmedical, Olympus, Oncopeptides, Saga, Salus, Siemens, Tangramed, Vialase.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731429</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731429-other-news-to-note-for-may-27-2026</link>
    </item>
    <item>
      <title>In the clinic for May 27, 2026</title>
      <description>
        <![CDATA[Clinical updates for biopharma and med tech, including data readouts and publications: Abivax, Biohaven, Bionano, Corbus, Eli Lilly, Gain, Genprex, Hologic, Kura, LIB, Nervgen, Renovorx, Sun, Virax.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731428</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731428-in-the-clinic-for-may-27-2026</link>
    </item>
    <item>
      <title>Financings for May 27, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Biostem, Cartesian, Editas, Hanchorbio, Kane, Mindmaze, Nanobiotix, Rani.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731427</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731427-financings-for-may-27-2026</link>
    </item>
    <item>
      <title>Appointments and advancements for May 27, 2026</title>
      <description>
        <![CDATA[New hires and promotions in the biopharma and med-tech industries, including: Breezebio, Decoy, Delphia, Metriopharm, Verastem.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731426</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731426-appointments-and-advancements-for-may-27-2026</link>
    </item>
    <item>
      <title>D&amp;D’s zabopegdutide shows more upbeat top-line phase II MASH data </title>
      <description>
        <![CDATA[D&D Pharmatech Inc. announced May 27 positive top-line tissue biopsy results of zabopegdutide (DD-01) from a 48-week phase II study of metabolic dysfunction-associated steatohepatitis (MASH), pushing company shares up 30% on the day.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731423</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731423-d-and-ds-zabopegdutide-shows-more-upbeat-top-line-phase-ii-mash-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-damage-fibrosis-cirrhosis.webp?t=1769528466" type="image/jpeg" medium="image" fileSize="677639">
        <media:title type="plain">Art concept for liver damage, such as fatty liver, fibrosis or cirrhosis</media:title>
      </media:content>
    </item>
    <item>
      <title>BMS-Hengrui deal strikes panic in Washington</title>
      <description>
        <![CDATA[On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd, Chairman John Moolenaar (R-MI), of the House Select Committee on the Chinese Communist Party, sent a letter to Treasury Secretary Scott Bessent urging him to add biotechnology as a prohibited technology under the Comprehensive Outbound Investment National Security (COINS) Act of 2025.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731422</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731422-bms-hengrui-deal-strikes-panic-in-washington</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-capital-washington-congress-government.webp?t=1588689267" type="image/png" medium="image" fileSize="2212023">
        <media:title type="plain">U.S. Capitol building</media:title>
      </media:content>
    </item>
    <item>
      <title>Initial data hint that US MFN pricing is hitting access in Europe</title>
      <description>
        <![CDATA[There are initial signs that President Donald Trump’s most-favored nation (MFN) policy may be further delaying access to new drugs in Europe, as companies hold off commercializing in these countries to avoid lower European prices being referenced in the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731421</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731421-initial-data-hint-that-us-mfn-pricing-is-hitting-access-in-europe</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/Map-of-Europe-medicine.webp?t=1720200739" type="image/jpeg" medium="image" fileSize="155822">
        <media:title type="plain">Medicine spilling onto map of Europe</media:title>
      </media:content>
    </item>
    <item>
      <title>Will Ovid’s golden age of KCC2 metamorph CNS?</title>
      <description>
        <![CDATA[The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in the space, where a handful of drug developers are known to be working. New York-based Ovid owns a portfolio of potential first-in-class direct activators of KCC2, and the firm detailed pharmacodynamic results along with the translational and clinical development strategy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731420</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731420-will-ovids-golden-age-of-kcc2-metamorph-cns</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Digital-brain-and-silhouette.webp?t=1692736287" type="image/jpeg" medium="image" fileSize="186512">
        <media:title type="plain">Digital brain and silhouette</media:title>
      </media:content>
    </item>
    <item>
      <title>Insulet initiates voluntary correction on Omnipod devices</title>
      <description>
        <![CDATA[Insulet Corp. has initiated a voluntary medical device correction affecting insulin pump pods in its Omnipod product lines after discovering a manufacturing issue that could lead to the leaking of insulin and the under-delivery of doses in some patients. The company said that some pods from specific lots may have a small tear in the cannula.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731419</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731419-insulet-initiates-voluntary-correction-on-omnipod-devices</link>
      <media:content url="https://www.bioworld.com/ext/resources/2023/05/08/OP5_INSU_POD_PDM_NoADH_RIGHT_RGB_With_Disclaimer.webp?t=1779905799" type="image/jpeg" medium="image" fileSize="69380">
        <media:title type="plain">Omnipod 5</media:title>
        <media:description type="plain">Omnipod 5. Credit: Insulet Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Apogee orbiting big AD market as Apex phase II data land</title>
      <description>
        <![CDATA[Apogee Therapeutics Inc. loaded up on what could total as much as $1.3 billion in financial fuel from Blackstone Life Sciences funds that will be used to propel zumilokibart (zumi), which yielded positive phase II results in atopic dermatitis (AD). A phase III experiment with the anti-IL-13 antibody is planned for the second half of this year, pending talks with regulators.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731418</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731418-apogee-orbiting-big-ad-market-as-apex-phase-ii-data-land</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Close-up-dermatitis-on-the-skin.webp?t=1754678599" type="image/jpeg" medium="image" fileSize="193819">
        <media:title type="plain">Close up dermatitis on the skin</media:title>
      </media:content>
    </item>
    <item>
      <title>Phase II AD study with zumilokibart scores for Apogee </title>
      <description>
        <![CDATA[A preview of the next edition of BioWorld, May 27, 2026]]>
      </description>
      <guid>http://www.bioworld.com/articles/731431</guid>
      <pubDate>Wed, 27 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731431-phase-ii-ad-study-with-zumilokibart-scores-for-apogee</link>
    </item>
    <item>
      <title>Today's news in brief</title>
      <description>
        <![CDATA[BioWorld briefs for May 27, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432891</guid>
      <pubDate>Wed, 27 May 2026 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/432891-todays-news-in-brief</link>
    </item>
    <item>
      <title>In the clinic for May 26, 2026</title>
      <description>
        <![CDATA[Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage, Aulos, Bicara, Biogen, Biontech, Black, Blossomhill, Boehringer, Denali, Eli Lilly, Fulgent, Immuneering, Inovio, Kelun-Biotech, Nuvalent, Olema, OSE, Regeneron, Remix, Rgenta, Sapience, Storm, SOBI, Zentalis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731414</guid>
      <pubDate>Wed, 27 May 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731414-in-the-clinic-for-may-26-2026</link>
    </item>
    <item>
      <title>Regulatory actions for May 26, 2026</title>
      <description>
        <![CDATA[Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Abbvie, Agios, Astellas, Astrazeneca, Boehringer, Daiichi, Gilead, Merck, Novo, Regeneron, Teva.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731416</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731416-regulatory-actions-for-may-26-2026</link>
    </item>
    <item>
      <title>Other news to note for May 26, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: 20/20 Biolabs, Skape.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731415</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731415-other-news-to-note-for-may-26-2026</link>
    </item>
    <item>
      <title>Financings for May 26, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Assembly, HCW, Jupiter, Nanobiotix, Nervgen, Synakis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731413</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731413-financings-for-may-26-2026</link>
    </item>
    <item>
      <title>Kennedy offers emergency immunity for use of MCM in hantavirus</title>
      <description>
        <![CDATA[Acknowledging that the spread of the Andes virus and the resulting disease, hantavirus pulmonary syndrome, “constitutes a credible risk of a future public health emergency,” U.S. Health and Human Services Secretary Robert Kennedy is issuing a declaration to provide liability protection for manufacturers, distributors and providers using favipiravir as a medical countermeasure (MCM) against the virus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731406</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731406-kennedy-offers-emergency-immunity-for-use-of-mcm-in-hantavirus</link>
    </item>
    <item>
      <title>FDA adcom to consider next iteration of COVID-19 vaccines</title>
      <description>
        <![CDATA[What would normally be a routine meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee May 28 may be more carefully watched given the overall turmoil surrounding vaccines in the U.S. The only task before the adcom is to recommend the COVID-19 vaccine formula for the upcoming season. That conversation will include looking at the effectiveness of the four FDA-approved vaccines currently in use in the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731405</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731405-fda-adcom-to-consider-next-iteration-of-covid-19-vaccines</link>
    </item>
    <item>
      <title>AhR you ready for this? A new (or not-so-new) approach in UC </title>
      <description>
        <![CDATA[Upbeat phase II news lately from Spyre Therapeutics Inc. in inflammatory bowel disease (IBD) perked not only the company’s stock but also wider interest in the buzzing space, where developers big and small are trying to tackle such chronic bedevilments as Crohn’s disease and ulcerative colitis (UC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/731404</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731404-ahr-you-ready-for-this-a-new-or-not-so-new-approach-in-uc</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/3D-illustration-of-human-digestive-system.webp?t=1709246262" type="image/jpeg" medium="image" fileSize="171684">
        <media:title type="plain">3D illustration of human digestive system</media:title>
      </media:content>
    </item>
    <item>
      <title>Work underway on vaccines, antivirals against rare Bundibugyo Ebola outbreak</title>
      <description>
        <![CDATA[Less than two weeks after the outbreak was officially declared, animal studies of a newly designed vaccine against the Bundibugyo Ebola virus are now underway in the U.S. and U.K., and the Serum Institute of India is standing ready to manufacture the vaccine for clinical trials. If the animal tests are positive, the vaccine will be ready for clinical trials in two to three months.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731403</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731403-work-underway-on-vaccines-antivirals-against-rare-bundibugyo-ebola-outbreak</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Ebola-virus-research.webp?t=1779828015" type="image/jpeg" medium="image" fileSize="128796">
        <media:title type="plain">Ebola virus in petri dish with lab, scientist background</media:title>
      </media:content>
    </item>
    <item>
      <title>Medtronic bolsters pain portfolio in $650M SPR Therapeutics buy </title>
      <description>
        <![CDATA[Medtronic plc is strengthening its pain management portfolio with its $650 million move to buy SPR Therapeutics Inc. and bring the company’s peripheral nerve stimulation system for sustained pain relief into its neuromodulation offering. The deal marks Medtronic’s third tuck-in deal so far this year, following its $585 million purchase of Cathworks Ltd. and $550 million acquisition of Scientia Vascular Inc., and is also a sign of the momentum in M&A activity in the medtech sector with other players making strategic acquisitions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731402</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731402-medtronic-bolsters-pain-portfolio-in-650m-spr-therapeutics-buy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/SPRINT-Device-Image_4clr-8.22.webp?t=1779820058" type="image/jpeg" medium="image" fileSize="65780">
        <media:title type="plain">SPR Therapeutic Inc.’s Sprint PNS system</media:title>
        <media:description type="plain">Sprint PNS system. Credit: SPR Therapeutics Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Lilly buys three vaccine makers; PCSK9 base editor shows promise</title>
      <description>
        <![CDATA[As the most active biopharma acquirer of 2026, Eli Lilly and Co. offered to buy three vaccine companies for up to $3.8 billion combined, while it simultaneously released positive early clinical results of a gene editing medicine brought into the fold last year through its buyout of Verve Therapeutics Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731401</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731401-lilly-buys-three-vaccine-makers-pcsk9-base-editor-shows-promise</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Syringes-in-virus-cell-company-logos.webp?t=1779831670" type="image/png" medium="image" fileSize="273178">
        <media:title type="plain">Syringes in virus cell; Lilly, Curevo, Limmatech, Vaccine Company   logos</media:title>
      </media:content>
    </item>
    <item>
      <title>Lilly buys three vaccine makers; PCSK9 base editor shows promise</title>
      <description>
        <![CDATA[A preview of the next edition of BioWorld, May 26, 2026]]>
      </description>
      <guid>http://www.bioworld.com/articles/731417</guid>
      <pubDate>Tue, 26 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731417-lilly-buys-three-vaccine-makers-pcsk9-base-editor-shows-promise</link>
    </item>
    <item>
      <title>Biggest gainers and losers for May 18-22, 2026</title>
      <description>
        <![CDATA[The top 10 biopharma stock gainers and losers for the week.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731411</guid>
      <pubDate>Tue, 26 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731411-biggest-gainers-and-losers-for-may-18-22-2026</link>
    </item>
    <item>
      <title>ICYMI: Week in review, May 18-22, 2026</title>
      <description>
        <![CDATA[A quick look back at top stories.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731410</guid>
      <pubDate>Tue, 26 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731410-icymi-week-in-review-may-18-22-2026</link>
    </item>
    <item>
      <title>Holiday notice</title>
      <description>
        <![CDATA[<em>BioWorld</em>'s offices were closed in observance of Memorial Day in the U.S. No issue was published Monday, May 25.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731409</guid>
      <pubDate>Tue, 26 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731409-holiday-notice</link>
    </item>
    <item>
      <title>Researchers identify innate immune barrier against melanoma</title>
      <description>
        <![CDATA[Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live melanoma cells, and the discovery could reshape thinking around macrophage-targeted cancer therapies and innate immunity in oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731270</guid>
      <pubDate>Tue, 26 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731270-researchers-identify-innate-immune-barrier-against-melanoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Phan-Lab-Garvan-Institute-Melanoma-imaging-05-26-26.webp?t=1779807535" type="image/jpeg" medium="image" fileSize="901145">
        <media:title type="plain">Microscopy of a cross-section of mouse skin containing melanoma tumors</media:title>
        <media:description type="plain">Microscopy of a cross-section of mouse skin containing melanoma tumors. CD169+ macrophages are shown in green and yellow, forming a distinct boundary as they attempt to locally contain the cancer. Credit: Phan Lab, Garvan Institute</media:description>
      </media:content>
    </item>
    <item>
      <title>Biopharma money raised: Jan. 1-May 21, 2026</title>
      <description>
        <![CDATA[Year-to-date money raised in public, private and other financings of biopharma companies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731438</guid>
      <pubDate>Fri, 22 May 2026 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731438-biopharma-money-raised-jan-1-may-21-2026</link>
    </item>
    <item>
      <title>Money raised by biopharma</title>
      <description>
        <![CDATA[Total raised in public, private and other financings of biopharma companies, comparing 2019-2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731437</guid>
      <pubDate>Fri, 22 May 2026 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731437-money-raised-by-biopharma</link>
    </item>
  </channel>
</rss>
